Janssen at EULAR 2015
The European League Against Rheumatism Annual Congress (EULAR) is one of the biggest events on the rheumatology calendar and is currently taking place in Rome, Italy. This annual event unites the scientific community with patient organisations to create a platform for educational and social exchange. More than 15,000 participants are anticipated to attend and Janssen is proud to share their latest research.
A total of 17 abstracts showcasing data from across the Janssen Immunology portfolio have been accepted for presentation. This is a clear demonstration of Janssen’s commitment to continued research and development of innovative solutions for the treatment of some of the most common immune and inflammatory diseases.
Did you know that common immune and inflammatory diseases such as psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis effect more than 200 million people globally.1,2,3 That’s a population almost as large as Brazil!4 Additional disease statistics broken down by country can be found at the Disease Lens.
We aim to provide new hope and better health for people and their families living with immune and inflammatory diseases. As we build upon existing discoveries and share our knowledge with internal and external partners, we will continue to help transform the field of immunology.
The commitment of Janssen to Immunology
1 Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14–ii17
2 Kuek A, Hazleman BL, Ostor AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251–260.
3 Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl III):iii8–iii18.
4 List of countries and dependencies by population. Available at https://en.wikipedia.org/wiki/List_of_countries_and_dependencies_by_population (Last accessed May 2015).